Outcomes and predictors of relapse and severe pneumonia in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder receiving inebilizumab: a prospective cohort study
Abstract
Background Inebilizumab was included in China’s national reimbursement drug list in 2023, enhancing its accessibility. However, there is a paucity of real-world data evaluating its performance in Chinese patients with aquaporin-4 immunoglobulin G–seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD). This prospective study therefore sought to assess the treatment outcomes and identify predictive factors for relapse and severe pneumonia in Chinese patients treated with Inebilizumab. Methods This study enrolled AQP4-IgG+ NMOSD patients receiving ≥1 dose of inebilizumab from March 2023 to June 2025. The primary outcome was time to first relapse. Secondary outcomes included annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, drug retention rates, and adverse events (AEs). Multivariate regression analyses were conducted to identify predictors of relapse and severe pneumonia. Results Among 136 patients (91.9% female; mean age 40.3 years; median treatment duration 13.8 months), the 12-month relapse-free rate was 88.1% (95% confidence interval [CI] =82.1–94.5%). Thirteen patients experienced 14 relapses, with 7 occurring within the first 6 months. The median time to first relapse was 5.2 months (range, 0.3–11.8). Risk factors for relapse within 12 months included: age at onset ≤ 20 years (hazard ratio [HR] 8.17, 95% CI = 1.96–34.03, p=0.004), disease duration >5 years (HR 8.06, 95% CI = 1.72–37.83, p=0.008), and pre-treatment relapses (HR…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 136 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.